The Cooper Companies, Inc. COO
Healthcare · Medical Instruments & Supplies · United States · S&P 500
Based on the available data, The Cooper Companies, Inc. gets an algorithmic score of 46/100. It trades at 56.63 $, with a bearish technical trend (RSI 35.4) and 32.0% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- Low-debt balance sheet.
Weaknesses
- —
Fundamentals
| P/E | 19.46 |
| Forward P/E | 12.06 |
| PEG | 0.52 |
| P/B | 1.29 |
| EV/EBITDA | 14.39 |
| P/S | 2.54 |
| ROE % | 6.84 |
| ROA % | 2.73 |
| Gross margin % | 65.93 |
| Operating margin % | 20.82 |
| Net margin % | 13.46 |
| Revenue growth % (y/y) | 0.60 |
| Earnings growth % (y/y) | 357.10 |
| Revenue CAGR % | 7.35 |
| Earnings CAGR % | -0.95 |
| Debt/Equity % | 33.63 |
| Current ratio | 1.22 |
| FCF yield % | 4.03 |
| Dividend yield % | 0.00 |
| Payout % | 0.00 |
Returns
| 1 month | -20.4 % |
| 3 months | -21.0 % |
| 6 months | -18.3 % |
| YTD | -30.2 % |
| 1 year | -16.2 % |
| 3 years | -31.1 % |
| 5 years | -46.9 % |
Risk
| 1-year volatility | 32.0 % |
| Beta | 0.71 |
| 5-year max drawdown | -52.1 % |
| Sharpe 1A | -0.51 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.